TARA · Protara Therapeutics, Inc.

$3.86 +0.04 (+1.05%) At close · Aug 31

Russell 2000 member Rebalance outlook locked

Market Cap

$225.74M

59.10M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-05-19	ISSVA poster: STARBORN-1: Interim Efficacy and Safety Data in Pediatric Participants with Macrocystic and Mixed-Cystic Lymphatic Malformations Treated with Intracystic Injection of TARA-002	Event
2026-05-19	AUA poster: ADVANCED-2 (Cohort A): Interim 12-Month Efficacy and Safety Data in BCG-Naïve Participants With High-Grade Non-Muscle Invasive Bladder Cancer	Event
2025-04-26	AUA poster: Preliminary Efficacy and Safety Results From ADVANCED-2: A Phase-2 Open-label Study of Intravesical TARA-002 In Adults With High-grade Non-muscle Invasive Bladder Cancer	Event
2024-12-05	SUO Poster - ADVANCED-2: Phase 2 Open-label Study to Evaluate Safety and Anti-tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer	Event
2022-05-12	ISSVA 2022 Poster – Retrospective Analysis of a Randomized Study and Open-Label Study to Evaluate the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations	Event

Source: https://protaratx.com/investors/

Key facts CIK 1359931 CUSIP 74365U107 13F (30d) 106 filings 106 filers Visit website Investor relations